3.4.17.21: Glutamate carboxypeptidase II
This is an abbreviated version!
For detailed information about Glutamate carboxypeptidase II, go to the full flat file.
Word Map on EC 3.4.17.21
-
3.4.17.21
-
tomography
-
positron
-
metastases
-
psma-targeted
-
node
-
lncap
-
tracer
-
prostatectomy
-
castration-resistant
-
modal
-
radioligands
-
androgen
-
psma-positive
-
radiotherapy
-
radionuclide
-
68ga-psma
-
biodistribution
-
radiotracers
-
neovasculature
-
radiopharmaceutical
-
mcrpc
-
theranostic
-
pelvic
-
gleason
-
psma-expressing
-
suvmax
-
restaging
-
oligometastatic
-
68ga-labeled
-
multiparametric
-
urea-based
-
spect
-
dosimetry
-
scintigraphy
-
abiraterone
-
castrate-resistant
-
n-acetylaspartate
-
extraprostatic
-
mpmri
-
pet-ct
-
enzalutamide
-
18f-labeled
-
positron-emission
-
tomography-computed
-
radium-223
-
pharmacology
-
radioimmunotherapy
-
medicine
-
tumor-to-background
-
analysis
-
radiometals
-
postprostatectomy
-
per-patient
-
diagnostics
-
drug development
- 3.4.17.21
-
tomography
-
positron
- metastases
-
psma-targeted
- node
-
lncap
-
tracer
-
prostatectomy
-
castration-resistant
-
modal
-
radioligands
- androgen
-
psma-positive
-
radiotherapy
-
radionuclide
-
68ga-psma
-
biodistribution
-
radiotracers
-
neovasculature
-
radiopharmaceutical
-
mcrpc
-
theranostic
-
pelvic
-
gleason
-
psma-expressing
-
suvmax
-
restaging
-
oligometastatic
-
68ga-labeled
-
multiparametric
-
urea-based
-
spect
-
dosimetry
-
scintigraphy
- abiraterone
-
castrate-resistant
- n-acetylaspartate
-
extraprostatic
-
mpmri
-
pet-ct
-
enzalutamide
-
18f-labeled
-
positron-emission
-
tomography-computed
-
radium-223
- pharmacology
-
radioimmunotherapy
- medicine
-
tumor-to-background
- analysis
-
radiometals
-
postprostatectomy
-
per-patient
- diagnostics
- drug development
Reaction
release of an unsubstituted, C-terminal glutamyl residue, typically from Ac-Asp-Glu or folylpoly-gamma-glutamates =
Synonyms
100 kDa ileum brush border membrane protein, Acetylaspartylglutamate dipeptidase, altered meristem program1, AMP1, Dipeptidase, acetylaspartylglutamate, EC 3.4.19.8, FGCP, folate hydrolase, folate hydrolase 1, FOLH1, Folylpoly-gamma-glutamate carboxypeptidase, folylpoly-gamma-glutamate carboxypeptidase II, GCP II, GCPII, GCPIII, glutamate carboxypeptidase, glutamate carboxypeptidase II, glutamate carboxypeptidase III, GPCPII, I100, Ileal dipeptidylpeptidase, Membrane glutamate carboxypeptidase, mGCP, More, N-acetyl-alpha-linked acidic dipeptidase, N-acetyl-alpha-linked acidic dipeptidase I, N-acetylaspartylglutamate peptidase, N-acetylated alpha-linked acid dipeptidase, N-Acetylated alpha-linked acidic dipeptidase, N-Acetylated-alpha-linked acidic dipeptidase, N-acetylated-alpha-linked acidic dipeptidase 2, N-acetylated-alpha-linked acidic dipeptidase II, N-Acetylated-alpha-linked-acidic dipeptidase, N-acetylated-alpha-linked-acidic-dipeptidase, N-Acetylated-alpha-linked-amino dipeptidase, NAADLADase, NAADLADse, NAAG degradation enzyme, NAAG peptidase, NAAG peptidase II, NAAG-hydrolyzing activity, NAALA dipeptidase, NAALADase, Naaladase I, NAALADase II, NLD I, PMSA, prostate specific membrane antigen, Prostate-specific membrane antigen, Prostate-specific membrane antigen homolog, prostate-specificmembrane antigen, Prostrate-specific membrane antigen, PSM, PSM antigen, PSMA, Pteroylpoly-gamma-glutamate carboxypeptidase, Rat NAAG peptidase
ECTree
3.4.17.21 Glutamate carboxypeptidase IIAdvanced search results
results (
results (Application
Application on EC 3.4.17.21 - Glutamate carboxypeptidase II
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
APPLICATION 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
analysis
synthesis of a series of PSMA-targeted 99mTc-chelate complexes, with core ligand 2-[3-(3-benzyloxycarbonyl-1-tert-butoxycarbonyl-propyl)-ureido]pentanedioic acid di-tert-butyl ester, for imaging PSMA-expressing human prostate cancer cells, in silico docking studies using the crystal structure of PSMA, overview. The method offers a potential for use in localizing prostate cancer masses, monitoring response to therapy, detecting prostate cancer recurrence following surgery, and selecting patients for subsequent PSMAtargeted chemotherapy
diagnostics
medicine
pharmacology
diagnostics
-
the enzyme, prostate-specific membrane antigen, is a good marker for prostate cancer
diagnostics
-
PSMA is a well-known imaging biomarker for staging and monitoring therapy, assessment of an 18F-labeled phosphoramidate peptidomimetic as a PSMA-targeted imaging agent for prostate cancer
diagnostics
-
PSMA overexpression in prostate cancer patients is related to a worse prognosis
diagnostics
the enzyme is an important diagnostic marker of prostate cancer progression
medicine
-
detection of cancerous cells in prostrate or blood, target for diagnostic and therapeutic strategies in prostrate cancer, immunotherapy, antibody therapy
medicine
-
design of inhibitors may lead to effective neuroprotective agents, possibility to employ GCPII inhibitors in stroke therapy
medicine
-
GCPII inhibitors are attractive candidates for clinical treatment trials in amylotrophic lateral sclerosis
medicine
-
inhibitors of NAADLADase protect against chronic glutamate-mediated motor neuron degeneration and may prove therapeutic towards amyotrophic lateral sclerosis
medicine
-
NAALADase inhibition may provide a new aproach for the treatment of both neurodegenerative disorders and peripheral neuropathies
medicine
-
the enzyme is an important marker in the diagnosis of prostate cancer
medicine
-
for establishing new strategies to treat peripheral neuropathies
medicine
glutamate carboxypeptidase II is a therapeutic target for neurodegeneration and prostate cancer
medicine
-
glutamate carboxypeptidase II may represent a viable therapeutic target for intervention on psychiatric disease
medicine
-
maternal total homocysteine concentration is affected by C1561T polymorphism, maternal GCPII C1561T variant is associated with neonatal methylmalonic acid concentration
medicine
urea-based, low molecular weight ligands of glutamate carboxypeptidase II have demonstrated efficacy in various models of neurological disorders and can serve as imaging agents for prostate cancer
medicine
-
enzyme is recognized as a major antigen during histoplasmosis. The titer against N-acetylated alpha-linked acidic dipeptidase is significantly increased in the patient sera
medicine
glutamate carboxypeptidase II is present in human blood, and its concentration within a healthy population varies between 1.3 and 17.2 ng/ml in volunteers not diagnosed with prostate cancer
medicine
glutamate carboxypeptidase II is effective in preclinical models of neurological disorders associated with excessive activation of glutamatergic systems. The study validates the use of hydroxamate-based inhibitors in the treatment of a chronic neurological disorder such as neuropathic pain
medicine
-
inhibitors of glutamate carboxypeptidase II with distinct chemical scaffolds are efficacious in several neurological models wherein excess glutamatergic transmission is presumed pathogenic. These include animal models of neuropathic pain, peripheral neuropathy, stroke, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, epilepsy, traumatic brain injury, addiction, and cognition
medicine
inhibitors of glutamate carboxypeptidase II with distinct chemical scaffolds are efficacious in several neurological models wherein excess glutamatergic transmission is presumed pathogenic. These include animal models of neuropathic pain, peripheral neuropathy, stroke, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, epilepsy, traumatic brain injury, addiction, and cognition
medicine
the enzyme is a putative target for the treatment of both prostate cancer and neuronal disorders associated with glutamate excitotoxicity
medicine
the enzyme is a reliable in vivo marker of re-endothelialisation after percutaneous vascular intervention and that glutamate carboxypeptidase II-positron emission tomography is the first non-invasive in vivo molecular imaging technique that can demonstrate and quantify re-endothelialisation. As a further perspective, well-powered studies in patients undergoing percutaneous vascular intervention need to confirm the potential of GCPII-PET for imaging the crucial process of arterial re-endothelialisation after injuring the vessel wall
medicine
the enzyme is an important diagnostic marker of prostate cancer progression and a putative target for the treatment of both prostate cancer and neuronal disorders associated with glutamate excitotoxicity. For the development of novel therapeutics, mouse models are used. Differences in enzymatic activity and inhibition profile are small. Therefore, mouse glutamate carboxypeptidase II can approximate human glutamate carboxypeptidase II in drug development and testing. On the other hand, significant differences in glutamate carboxypeptidase II tissue expression must be taken into account when developing novel glutamate carboxypeptidase II-based anticancer and therapeutic methods, including targeted anticancer drug delivery systems, and when using mice as a model organism
medicine
-
enzyme is recognized as a major antigen during histoplasmosis. The titer against N-acetylated alpha-linked acidic dipeptidase is significantly increased in the patient sera
-
pharmacology
-
enzyme inhibitors are used in therapy of neruological disorders, overview
pharmacology
the enzyme is a drug target in neuronal damage and prostate cancer
pharmacology
-
the enzyme is a target for specific inhibitor design in therapy of neurodegenerative disorders, overview
pharmacology
-
the enzyme NAALADase is a target for drug treatment in neuropathic pain
pharmacology
-
effects of PSMA-targeted photodynamic therapy on cytoskeletal networks in prostate cancer cells
pharmacology
-
PSMA is a target for imaging and therapeutic applications for prostate cancer
pharmacology
-
usage of the ectodomain of PSMA as target for a retargeted measles virus, that harbors a single-chain antibody specific for the extracellular domain of PSMA (J591) inserted as a C-terminal extension on its viral attachment protein. Live attenuated vaccine strain of measles virus has promising antitumor activity. Fully retargeted MV that infects cells exclusively through the PSMA receptor, which is overexpressed on prostate cancer cells and tumor neovasculature, method, overview. The construct leads to tumor regression
